Skip to main content
SpringerLink
Log in

Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Demaerschalk BM, Kleindorer DO, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy El Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE, American Heart Association Stroke Council and Council on Epidemiology and Prevention (2016) Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke. Stroke 47:581–641

    Article  PubMed  Google Scholar 

  2. Diener HC, Bernstein R, Butcher K, Campbell B, Cloud G, Davalos A, Davis S, Ferro JM, Grond M, Krieger D, Ntaios G, Slowik A, Touzé E (2016) Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expert opinion. Int J Stroke 12:9–12

    Article  PubMed  Google Scholar 

  3. Berrouschot J, Stoll A, Hogh T, Eschenfelder CC (2016) Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke 47:1936–1938

    Article  CAS  PubMed  Google Scholar 

  4. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Jam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520

    Article  CAS  PubMed  Google Scholar 

  5. Schmohl M, Glund S, Harada A, Imazu S, De Smet M, Moschetti V, Ramael S, Ikushima I, Grünenfelder F, Reilly P, Stangeri J (2016) Idarucizumab does not have procoagulant effects: assessment of thrombosis biomarkers in healthy volunteers. Thromb Haemost. doi:10.1160/TH16-05-0385

    PubMed  Google Scholar 

  6. Schafter N, Muller A, Wullner U (2016) Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab – a case report. J Stroke Cerebrovasc Dis 25:e126–e127

    Article  Google Scholar 

  7. Kafke W, Kraft P (2016) Intravenous thrombolysis after reversal of dabigatran by idarucizumab: a case report. Case Rep Neurol 8:140–144

    Article  PubMed  PubMed Central  Google Scholar 

  8. Schulz JG, Kreps B (2016) Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke. J Neurol Sci 370:44

    Article  PubMed  Google Scholar 

  9. Mutzenbach JS, Pikija S, Otto F, Halwachs U, Weymayr F, Sellner J (2016) Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab–a case report. Ann Clin Transl Neurol 3:889–892

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gawehn A, Ayari Y, Heuschkel C, Kaste M, Kermer P (2016) Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report. J Med Case Rep 10:269

    Article  PubMed  PubMed Central  Google Scholar 

  11. Zhang J, Yang Y, Sun J, Xing Y (2014) Hemorrhagic transformation after cerebral infarction: current concepts and challenges. Ann Transl Med 2:81

    PubMed  PubMed Central  Google Scholar 

  12. Ay H, Gungor L, Arsava EM, Rosand J, Vangel M, Benner T, Schwamm LH, Furie KL, Koroshetz WJ, Sorensen AG (2010) A score to predict early risk of recurrence after ischemic stroke. Neurology 72:128–135

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Northern Health, Epping, Melbourne, VIC, 3076, Australia

    Felix C. Ng, James Bice, Anne Rodda, Matthew Lee-Archer & Douglas E. Crompton

Authors
  1. Felix C. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Bice
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Rodda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matthew Lee-Archer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Douglas E. Crompton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felix C. Ng.

Ethics declarations

Consent for case reports

Written consents were obtained by patient and families.

Conflicts of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ng, F.C., Bice, J., Rodda, A. et al. Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis. J Neurol 264, 591–594 (2017). https://doi.org/10.1007/s00415-017-8410-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-017-8410-6

Keywords

Search

Navigation